BMEA Insider Trading Activity and SEC Form 4 Filings
BMEA insider trading summary
Over the past 12 months, insiders at Biomea Fusion, Inc. (BMEA) reported 4 open-market purchases worth $197K by 2 insiders and no sales on SEC Form 4. Net insider buying was $197K.
Latest BMEA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 11, 2025 | Rainer M Erdtmann | See Remarks | Buy | $43K (30,000 @ $1.43) |
| Dec 2, 2025 | Michael J.M. Hitchcock | Interim CEO | Buy | $99K (100,000 @ $0.99) |
| Dec 1, 2025 | Rainer M Erdtmann | See Remarks | Buy | $11K (10,000 @ $1.05) |
| Nov 28, 2025 | Rainer M Erdtmann | See Remarks | Buy | $44K (40,000 @ $1.10) |
| Sep 30, 2024 | Michael J.M. Hitchcock | Insider | Buy | $101K (10,000 @ $10.06) |
| Jun 11, 2024 | Franco Valle | Chief Financial Officer | Buy | $55K (12,509 @ $4.43) |
| Jun 1, 2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sell | $1.7M (50,000 @ $34.56) |
| May 31, 2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sell | $2.5M (75,000 @ $33.81) |
| May 12, 2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sell | $846K (25,000 @ $33.84) |
| May 9, 2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sell | $5.2M (150,000 @ $34.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.